KR20240102916A - Sars-cov-2를 표적으로 하는 단일 도메인 항체 - Google Patents

Sars-cov-2를 표적으로 하는 단일 도메인 항체 Download PDF

Info

Publication number
KR20240102916A
KR20240102916A KR1020237012502A KR20237012502A KR20240102916A KR 20240102916 A KR20240102916 A KR 20240102916A KR 1020237012502 A KR1020237012502 A KR 1020237012502A KR 20237012502 A KR20237012502 A KR 20237012502A KR 20240102916 A KR20240102916 A KR 20240102916A
Authority
KR
South Korea
Prior art keywords
seq
cdr3
cdr2
single domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012502A
Other languages
English (en)
Korean (ko)
Inventor
지안동 후오
레이몬드 오웬스
제임스 나이스미스
Original Assignee
더 로잘린드 프랭클린 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2014451.5A external-priority patent/GB202014451D0/en
Priority claimed from GBGB2014453.1A external-priority patent/GB202014453D0/en
Priority claimed from GBGB2108319.1A external-priority patent/GB202108319D0/en
Application filed by 더 로잘린드 프랭클린 인스티튜트 filed Critical 더 로잘린드 프랭클린 인스티튜트
Publication of KR20240102916A publication Critical patent/KR20240102916A/ko
Pending legal-status Critical Current

Links

Classifications

    • C07K16/1003—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237012502A 2020-09-14 2021-09-14 Sars-cov-2를 표적으로 하는 단일 도메인 항체 Pending KR20240102916A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2014453.1 2020-09-14
GBGB2014451.5A GB202014451D0 (en) 2020-09-14 2020-09-14 Single domain antibodies
GB2014451.5 2020-09-14
GBGB2014453.1A GB202014453D0 (en) 2020-09-14 2020-09-14 Linker
GBGB2108319.1A GB202108319D0 (en) 2021-06-10 2021-06-10 Single domain antibodies
GB2108319.1 2021-06-10
PCT/GB2021/052383 WO2022053839A1 (en) 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2

Publications (1)

Publication Number Publication Date
KR20240102916A true KR20240102916A (ko) 2024-07-03

Family

ID=77951755

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012502A Pending KR20240102916A (ko) 2020-09-14 2021-09-14 Sars-cov-2를 표적으로 하는 단일 도메인 항체

Country Status (7)

Country Link
US (1) US20230374116A1 (https=)
EP (1) EP4211157A1 (https=)
JP (1) JP2023542107A (https=)
KR (1) KR20240102916A (https=)
AU (1) AU2021339978A1 (https=)
CA (1) CA3192456A1 (https=)
WO (1) WO2022053839A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
CN117603358B (zh) * 2023-02-24 2024-11-01 中国科学院微生物研究所 一种广谱新型冠状病毒的双特异性抗体
CN118255878A (zh) * 2024-04-15 2024-06-28 深圳细胞谷生物医药有限公司 SARS-CoV-2驼源纳米抗体或其抗原结合片段、及其组合物和应用
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법

Also Published As

Publication number Publication date
WO2022053839A1 (en) 2022-03-17
EP4211157A1 (en) 2023-07-19
US20230374116A1 (en) 2023-11-23
JP2023542107A (ja) 2023-10-05
AU2021339978A9 (en) 2024-10-10
AU2021339978A1 (en) 2023-05-04
CA3192456A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
KR20240102916A (ko) Sars-cov-2를 표적으로 하는 단일 도메인 항체
RU2739946C2 (ru) Антитела к фактору xi и способы их применения
KR102687212B1 (ko) Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
KR102918597B1 (ko) 항-인자 XI/XIa 항체를 사용한 치료 방법
WO2010081173A2 (en) Modified antibody compositions, methods of making and using thereof
KR20230016186A (ko) 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
JP2024023278A (ja) Ａｌｋ７結合タンパク質およびその使用
CN112638932A (zh) 人源性抗(聚-ga)二肽重复序列(dpr)抗体
US20230357364A1 (en) Covid-19 antibodies and uses thereof
Song et al. Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
CN119053624A (zh) 生长激素受体靶向多肽
CN111320687B (zh) 抗h7n9全人源单克隆抗体4e18及其制备方法与应用
EP4217386A1 (en) Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
CN117042799A (zh) 靶向sars-cov-2的单结构域抗体
CN111434683B (zh) 抗h7n9全人源单克隆抗体8d11及其制备方法与应用
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
Fu et al. The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2
RU2847356C2 (ru) Антитела к фактору xi и способы их применения
CN117886942A (zh) 抗人msln抗体及其应用
HK40106013A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40106012A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
KR20260051471A (ko) Alk7 결합 단백질 및 이의 용도
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000